SCHEMBL3362889

SCHEMBL3362889

C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 4/20 0.70
LMNA P02545 3/20 0.70
CYP3A4 P08684 3/20 0.70
MEN1 O00255 3/20 0.70
KMT2A Q03164 3/20 0.70
SHBG P04278 2/20 0.70
SERPINA6 P08185 2/20 0.70
G6PD P11413 2/20 0.70
MAPK1 P28482 1/20 0.70
HSD17B3 P37058 1/20 0.70
PMP22 Q01453 1/20 0.70
AKR1B10 O60218 1/20 0.70
AKR1B1 P15121 1/20 0.70
CYP2D6 P10635 1/20 0.70
TSHR P16473 1/20 0.70
NFKB1 P19838 1/20 0.70
CYP2C19 P33261 1/20 0.70
ABL1 P00519 1/20 0.51
RIN1 Q13671 1/20 0.51
GABRA1 P14867 5/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892804 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL11004575 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL1799883 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL15463390 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL20058395 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL4890316 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL6938662 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL1800894 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL14525640 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A
SCHEMBL4893508 1.00 GPBAR1 (0.70) GPBAR1LMNACYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562182-A1 BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2025-06-04 EP claimed
WO-2023233945-A1 BILIARY TRACT CANCER TESTING METHOD 株式会社日立ハイテク 2023-12-07 WO claimed
US-20230085402-A1 BIOMARKERS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-03-16 US claimed
WO-2022251309-A2 PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SIOLTA THERAPEUTICS, INC. (US) 2022-12-01 WO claimed
WO-2017189528-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME Ecolab USA, Inc. (US) 2017-11-02 WO claimed
US-20170306504-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME CHAMPIONX LLC 2017-10-26 US claimed
US-20150071857-A1 STEROID HORMONE AND CHOLESTEROL PATHWAYS AS ONE UNIFIED HOMEOSTATIC SYSTEM LIGAND PHARMACEUTICALS, INC. 2015-03-12 US claimed
EP-2822556-A1 STEROID HORMONE AND CHOLESTEROL PATHWAYS AS ONE UNIFIED HOMESTATIC SYSTEM Ligand Pharmaceuticals Inc. (US) 2015-01-14 EP claimed
US-20130234071-A1 COMPOSITION OF HUMAN SYNTHETIC URINE DENEAU JOEL DAVID (US) 2013-09-12 US claimed
WO-2013134311-A1 STEROID HORMONE AND CHOLESTEROL PATHWAYS AS ONE UNIFIED HOMESTATIC SYSTEM LIGAND PHARMACEUTICALS, INC. (US) 2013-09-12 WO claimed
EP-4740024-A1 ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS The University Court Of The University of Edinburgh (GB) 2026-05-13 EP disclosed
US-20250388973-A1 MULTI-OMICS ASSESSMENT PROGNOMIQ INC (US) 2025-12-25 US disclosed
EP-4608419-A1 METHODS OF GENERATING HORMONE-PRODUCING ORGANOIDS AND REVERSING HYPOGONADISM Jangobio, LLC (US) 2025-09-03 EP disclosed
US-12329726-B2 Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-06-17 US disclosed
EP-4562182-A1 BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2025-06-04 EP disclosed
US-20140017675-A1 ULTRA-HIGH-SENSITIVE ASSAY OF PROTEIN AND NUCLEIC ACID AND KIT, AND NOVEL ENZYME SUBSTRATE Nakaishi, Kazunari (JP) 2014-01-16 US disclosed
WO-2013134311-A1 STEROID HORMONE AND CHOLESTEROL PATHWAYS AS ONE UNIFIED HOMESTATIC SYSTEM LIGAND PHARMACEUTICALS, INC. (US) 2013-09-12 WO disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-20080033046-A1 Treatment of myocardial infarction with 11HSD1 inhibitors UNIVERSITY OF EDINBURGH (GB) 2008-02-07 US disclosed
US-20060019400-A1 Method for the determination of glucuronides in physiological samples UNIVERSITY OF MARYLAND (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A GPBAR1 589/4885LMNA 692/4885CYP3A4 403/4885
US-20250388973-A1 MULTI-OMICS ASSESSMENT S100A4, APOL1, SAAL1 GPBAR1 3843/4885LMNA 2789/4885CYP3A4 1840/4885
US-20080033046-A1 Treatment of myocardial infarction with 11HSD1 inhibitors HSD11B1, HSD11B2, CYP11B1 GPBAR1 533/4885LMNA 4376/4885CYP3A4 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.